# US 12,600,799 B2 · Anti-IgG nanobodies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,600,799 B2 - Document ID: US12600799B2 - Status: Granted - Kind: B2 - Application number: 16/754,847 - Filed: 2018-10-11 - Published: 2024-01-18 - Granted: 2026-04-14 - Earliest claimed: 2017-10-11 - Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. - Applicants: Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E.V. - Inventors: Dirk Görlich; Tino Pleiner - Web page: https://patentgrep.com/patent/US12600799B2 ## CPC - C07K 16/42: against immunoglobulins - C07K 2317/22: from camelids, e.g. camel, llama or dromedary - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention relates to novel anti-IgG nanobodies, particularly nanobodies directed against rabbit or mouse IgG. Further, the invention relates to the use of said nanobodies and methods for producing them. ## Claims ### Claim 1 A combination comprising a plurality of different single domain antibodies or a plurality of different immune complexes comprising a single domain antibody bound to an IgG antibody, wherein the single domain antibodies are selected from a combination of several single domain antibodies recognizing the same type of IgG molecules, which bind to non-overlapping epitopes on said IgG molecules, wherein the single domain antibodies are selected from: (i) single domain antibodies directed against rabbit IgG of SEQ ID NOs. 1 or 2; or (ii) single domain antibodies directed against mouse IgG of SEQ ID NOs. 3-34. ### Claim 2 (depends on 1) The combination according to claim 1, wherein the single domain antibodies are selected from a combination of (i) single domain antibodies of SEQ ID NO. 5 and SEQ ID NO. 8, (ii) single domain antibodies of SEQ ID NO. 8 and SEQ ID NO. 19, (iii) single domain antibodies of SEQ ID NO. 18 and SEQ ID NO. 19, (iv) single domain antibodies of SEQ ID NO. 5 and SEQ ID NO. 18, (v) single domain antibodies of SEQ ID NO. 5 and SEQ ID NO. 25, or (vi) single domain antibodies comprising the sequences as shown in SEQ ID NO. 1 and SEQ ID NO. 2. ### Claim 3 (depends on 1) The combination according to claim 1, wherein the single domain antibodies are selected from a combination of 2 or 3 single domain antibodies. ### Claim 4 (depends on 1) The combination according to claim 1, wherein the same type of IgG molecules are selected from the group consisting of mouse IgG1, mouse IgG2a and rabbit IgG. ### Claim 5 (depends on 1) The combination according to claim 1, wherein said non-overlapping epitopes on said IgG molecules are epitopes on different regions on said IgG molecules. ### Claim 6 (depends on 5) The combination according to claim 5, wherein said different regions on said IgG molecules are selected from the group consisting of a light chain, a κ and/or λ light chain, and a Fc or hinge fragment of said IgG molecules. ### Claim 7 (depends on 5) The combination according to claim 5, wherein said epitopes are on the light chain of said IgG molecules. ### Claim 8 (depends on 5) The combination according to claim 5, wherein said epitopes are on the κ and/or λ light chain of said IgG molecules. ### Claim 9 (depends on 5) The combination according to claim 5, wherein said epitopes are on the Fc or hinge fragment of said IgG molecules. ### Claim 10 A combination comprising a plurality of different single domain antibodies or a plurality of different immune complexes comprising a single domain antibody bound to an IgG antibody, wherein the single domain antibodies are selected from a combination of several single domain antibodies recognizing the same type of IgG molecules, which bind to non-overlapping epitopes on said IgG molecules, wherein at least one single domain antibody of said combination (i) is directed against rabbit IgG of SEQ ID NOs. 1 or 2; or (ii) is directed against mouse IgG of SEQ ID NOs. 3-34. ### Claim 11 A combination comprising a plurality of different single domain antibodies comprising a single domain antibody bound to an IgG antibody, wherein the single domain antibodies are selected from a combination of several single domain antibodies recognizing the same type of IgG molecules, which bind to non-overlapping epitopes on said IgG molecules, wherein the single domain antibodies are selected from a combination of: (i) the single domain antibodies comprising amino acid sequences of SEQ ID NO. 5 and SEQ ID NO. 8; (ii) the single domain antibodies comprising the amino acid sequence of SEQ ID NO. 8 and SEQ ID NO. 19; (iii) the single domain antibodies comprising the amino acid sequences of SEQ ID NO. 18 and SEQ ID NO. 19; (iv) the single domain antibodies comprising the amino acid sequences of SEQ ID NO. 5 and SEQ ID NO. 18; (v) the single domain antibodies comprising the amino acid sequences of SEQ ID NO. 5 and SEQ ID NO. 25; or (vi) the single domain antibodies comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2.